# Exploring Potential Drug-Drug Interactions: A Cross-Sectional Study of 1 Million e-Prescriptions Across Medical Specialties in Shiraz, Iran (2021-2024)

**Authors:** Pedram Porbaha, Mohammad Hasannejad, Negar Ahvar, Mojtaba Shafiekhani, Nahid Abolpour, Mehrdad Sharifi

PMC · DOI: 10.30476/ijms.2025.106551.4081 · Iranian Journal of Medical Sciences · 2026-02-01

## TL;DR

This study analyzed 1 million e-prescriptions in Iran to identify common drug-drug interactions across medical specialties, highlighting the need for improved patient safety measures.

## Contribution

A large-scale, multi-specialty analysis of DDIs in Iran using real-world e-prescription data, revealing specialty-specific patterns and high-risk drug combinations.

## Key findings

- 38.77% of prescriptions contained at least one C, D, or X DDI.
- Rheumatology, endocrinology, and orthopedics had the highest rates of high-risk DDIs.
- Dexamethasone, ketorolac, quetiapine, and aspirin were most commonly involved in DDIs.

## Abstract

Drug-drug interactions (DDIs) are among the most important medical errors that can lead to adverse effects, increased toxicity, or reduced treatment efficacy. The frequency and severity of DDIs vary across specialties. However, studies covering multiple specialties in Iran are few and not up-to-date. This study aims to fill this gap by offering a large-scale, multi-specialty analysis of DDIs in Iran using real-world e-prescription data.

This study analyzed pharmacological DDIs in 1,049,769 e-prescription records from Shiraz, Iran, spanning from November 2021 to February 2024. We used Lexicomp® DDI checker software and Python programming language to identify the most prevalent DDIs overall, the top contributing drug specialties for each of those DDIs, the specialties with the highest rates of potential DDIs, and the most prevalent DDI within each specialty.

The analysis revealed that 38.77% of prescriptions contained at least one C, D, or X DDI. Dexamethasone, ketorolac, quetiapine, and aspirin were the drugs most commonly involved. The most frequent DDIs occurred between aprepitant and dexamethasone, ketorolac, and naproxen, aprepitant and doxorubicin, prednisolone, and tacrolimus, and diclofenac sodium and ketorolac. The medical specialties with the highest incidence of D or X level DDIs were rheumatology, endocrinology, orthopedics, oncology, internal medicine, emergency services, and psychiatry. The average counts of D or X DDIs per prescription were 0.53, 0.41, 0.40, 0.40, 0.26, 0.24, and 0.23, respectively.

This study underscores the need for provider vigilance and proactive measures, such as training and e-prescription alerts, to ensure patient safety.

## Linked entities

- **Chemicals:** dexamethasone (PubChem CID 5743), ketorolac (PubChem CID 3826), quetiapine (PubChem CID 5002), aspirin (PubChem CID 2244), aprepitant (PubChem CID 135413536), doxorubicin (PubChem CID 31703), prednisolone (PubChem CID 5755), tacrolimus (PubChem CID 445643), diclofenac sodium (PubChem CID 5018304), naproxen (PubChem CID 1302)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}
- **Diseases:** hypoglycemia (MESH:D007003), COVID-19 (MESH:D000086382), diabetes (MESH:D003920), bone marrow toxicity (MESH:D001855), gastrointestinal (GI) toxicity (MESH:D005767), toxicity (MESH:D064420), rheumatology (MESH:D012216), inflammation (MESH:D007249), autoimmune care (MESH:D003428), C, D, or X DDI (MESH:D019701), hematologic toxicity (MESH:D006402), pain (MESH:D010146), DDIs (MESH:D000081015), autoimmune diseases (MESH:D001327), liver toxicity (MESH:D056486)
- **Chemicals:** hydrochlorothiazide (MESH:D006852), Dexamethasone (MESH:D003907), Granisetron (MESH:D017829), Capecitabine (MESH:D000069287), losartan potassium (MESH:D019808), palonosetron (MESH:D000077924), valproate Sodium (MESH:D014635), Leflunomide (MESH:D000077339), clopidogrel (MESH:D000077144), Platinum (MESH:D010984), D (MESH:D003903), D or X (-), prednisolone (MESH:D011239), naproxen (MESH:D009288), Salt (MESH:D012492), tacrolimus (MESH:D016559), doxorubicin (MESH:D004317), Taxane (MESH:C080625), amlodipine (MESH:D017311), simvastatin (MESH:D019821), Pantoprazole (MESH:D000077402), quetiapine (MESH:D000069348), Docetaxel (MESH:D000077143), dextrose (MESH:D005947), Oxaliplatin (MESH:D000077150), Aprepitant (MESH:D000077608), aspirin (MESH:D001241), Methotrexate (MESH:D008727), diclofenac sodium (MESH:D004008), metformin (MESH:D008687), ketorolac (MESH:D020910), dapoxetine (MESH:C080598)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929907/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929907/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929907/full.md

---
Source: https://tomesphere.com/paper/PMC12929907